Edrophonium is a drug used for the treatment of myasthenia gravis, a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness, which results from antibodies that block or destroy nicotinic receptors at the junction between the nerve and muscle. By blocking cholinesterase, an enzyme which demolish acetylcholine, it increases the amount of acetylcholine in the neuromuscular junction improving the muscle weakness
